Ewha Med J.  2022 Jul;45(3):e4. 10.12771/emj.2022.e4.

Screening and Management for Dyslipidemia in Korean Children and Adolescents

• Yoon JS
• Hwang IT

• KMID: 2532210
• DOI: http://doi.org/10.12771/emj.2022.e4

Abstract

Cardiovascular disease (CVD) is the most common cause of death worldwide, and dyslipidemia is a major risk factor. Atherosclerosis can begin in childhood and continue into adulthood, thereby contributing to CVD development. Obesity is the most common cause of dyslipidemia, and the prevalence of childhood obesity and dyslipidemia is increasing worldwide, making it a public health concern. As clinical evidence has accumulated, guidelines for dyslipidemia in children have been continuously revised since 1992. The limitations of screening tests for individuals with a family history of dyslipidemia emphasize the necessity of universal screening, and non-HDL cholesterol assessment is recommended as a screening test for dyslipidemia in children. The guidelines for dyslipidemia in Korean children and adolescents published in 2017 recommend that non-HDL cholesterol screening tests be performed in non-fasting conditions at 9–11 years and 17–21 years of age. The main purpose of this article is to describe the history and rationale of lipid screening recommendations in children and adolescents and to review the currently recommended screening methods and treatments for dyslipidemia. (Ewha Med J 2022;45(3):e4)

Keyword

Dyslipidemias; Children; Adolescent; Diagnosis

Reference

References

1. Korean Statistical Information Service. Annual report on the cause of death statistics [Internet]. Daejeon (KR): Korean Statistical Information Service;c2020. [cited 2021 Aug 28]. Available from. https://kosis.kr/search/search.do.

2. World Health Organization. The global burden of disease 2004 Update [Internet]. Geneva (CH): World Health Organization;c2004. [cited 2012 Jun 16]. Available from. https://apps.who.int/iris/handle/10665/43942.

3. Becque MD, Katch VL, Rocchini AP, Marks CR, Moorehead C. Coronary risk incidence of obese adolescents: reduction by exercise plus diet intervention. Pediatrics. 1988; 81:605–612. DOI: 10.1542/peds.81.5.605. PMID: 3357722.

4. Kim RB, Kim BG, Kim YM, Seo JW, Lim YS, Kim HS, et al. Trends in the incidence of hospitalized acute myocardial infarction and stroke in Korea, 2006–2010. J Korean Med Sci. 2013; 28:16–24. DOI: 10.3346/jkms.2013.28.1.16. PMID: 23341707. PMCID: PMC3546096.

5. Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013; 7:14–24. DOI: 10.1007/s11684-013-0262-6. PMID: 23471659. PMCID: PMC3936017.

6. Nogueira-de-Almeida CA. Metabolic syndrome definition in adolescents should incorporate insulin resistance. Ann Pediatr Endocrinol Metab. 2020; 25:287–288. DOI: 10.6065/apem.2040166.083. PMID: 33401885. PMCID: PMC7788337.

7. Castorani V, Polidori N, Giannini C, Blasetti A, Chiarelli F. Insulin resistance and type 2 diabetes in children. Ann Pediatr Endocrinol Metab. 2020; 25:217–226. DOI: 10.6065/apem.2040090.045. PMID: 33401880. PMCID: PMC7788344.

8. Yoo SE, Lee JH, Lee JW, Park HS, Lee HA, Kim HS. Increasing prevalence of fasting hyperglycemia in adolescents aged 10–18 years and its relationship with metabolic indicators: the Korea National Health and Nutrition Examination Study (KNHANES), 2007–2018. Ann Pediatr Endocrinol Metab. 2022; 27:60–68. DOI: 10.6065/apem.2142068.034. PMID: 33971707. PMCID: PMC8984745.

9. Kim J, Lee J. Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. Ann Pediatr Endocrinol Metab. 2021; 26:1–13. DOI: 10.6065/apem.2040188.094. PMID: 33819954. PMCID: PMC8026341.

10. Kim J, Moon JS. Secular trends in pediatric overweight and obesity in Korea. J Obes Metab Syndr. 2020; 29:12–17. DOI: 10.7570/jomes20002. PMID: 32188238. PMCID: PMC7118001.

11. Song K, Jeon S, Lee HS, Choi HS, Suh J, Kwon A, et al. Trends of dyslipidemia in Korean youth according to sex and body mass index: based on the Korea National Health and Nutrition Examination Survey (2007–2018). J Pediatr. 2021; 237:71–78. DOI: 10.1016/j.jpeds.2021.06.010. PMID: 34144029.

12. Yang S, Hwang JS, Park HK, Lee HS, Kim HS, Kim EY, et al. Serum lipid concentrations, prevalence of dyslipidemia, and percentage eligible for pharmacological treatment of Korean children and adolescents; data from the Korea National Health and Nutrition Examination Survey IV (2007–2009). PLOS ONE. 2012; 7:e49253. DOI: 10.1371/journal.pone.0049253. PMID: 23251338. PMCID: PMC3522657.

13. Kim SH, Ahn BC, Joung H, Park MJ. Lipid profiles and prevalence of dyslipidemia in Korean adolescents. Endocrinol Metab. 2012; 27:208–216. DOI: 10.3803/EnM.2012.27.3.208.

14. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. J Am Med Assoc. 2003; 290:2277–2283. DOI: 10.1001/jama.290.17.2277. PMID: 14600186.

15. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med. 2019; 34:723–771. DOI: 10.3904/kjim.2019.188. PMID: 31272142. PMCID: PMC6610190.

16. Jialal I. A practical approach to the laboratory diagnosis of dyslipidemia. Am J Clin Pathol. 1996; 106:128–138. DOI: 10.1093/ajcp/106.1.128. PMID: 8701923.

17. American Academy of Pediatrics. National Cholesterol Education Program (NCEP): report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992; 89:495–501. DOI: 10.1542/peds.89.3.495.

18. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003; 157:821–827. DOI: 10.1001/archpedi.157.8.821. PMID: 12912790.

19. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics. 2011; 128:S213–S256. DOI: 10.1542/peds.2009-2107C. PMID: 22084329. PMCID: PMC4536582.

20. Kavey REW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003; 107:1562–1566. DOI: 10.1161/01.CIR.0000061521.15730.6E. PMID: 12654618.

21. Zimmet P, Alberti KGMM, Kaufman F, Tajima N, Silink M, Arslanian S. The metabolic syndrome in children and adolescents: an IDF consensus report. Pediatr Diabetes. 2007; 8:299–306. DOI: 10.1111/j.1399-5448.2007.00271.x. PMID: 17850473.

22. Shim YS, Baek JW, Kang MJ, Oh YJ, Yang S, Hwang IT. Reference values for the triglyceride to high-density lipoprotein cholesterol ratio and non-high-density lipoprotein cholesterol in Korean children and adolescents: the Korean National Health and Nutrition Examination Surveys 2007–2013. J Atheroscler Thromb. 2016; 23:1334–1344. DOI: 10.5551/jat.35634. PMID: 27373984. PMCID: PMC5221496.

23. Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation. 2009; 119:1108–1115. DOI: 10.1161/CIRCULATIONAHA.108.816769. PMID: 19221218.

24. Lim JS, Kim EY, Kim JH, Yoo JH, Yi KH, Chae HW, et al. 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents. Clin Exp Pediatr. 2020; 63:454–462. DOI: 10.3345/cep.2020.01340. PMID: 33264558. PMCID: PMC7738765.

25. Sperling M. Sperling pediatric endocrinology. 5th ed. Philadelphia: Elsevier;2020.

26. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013; 5:1218–1240. DOI: 10.3390/nu5041218. PMID: 23584084. PMCID: PMC3705344.

27. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2008; 93:4200–4209. DOI: 10.1210/jc.2008-1270. PMID: 18697860.

28. de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019; 139:e603–e634. DOI: 10.1161/CIR.0000000000000618.

29. NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP): highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992; 89:495–501. DOI: 10.1542/peds.89.3.495.

30. US Preventive Services Task Force [USPST]. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics. 2007; 120:e215–e219. DOI: 10.1542/peds.2006-1812. PMID: 17606545.

31. Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia: the muscatine study. J Am Med Assoc. 1990; 264:3034–3038. DOI: 10.1001/jama.1990.03450230070031.

32. Eissa MA, Wen E, Mihalopoulos NL, Grunbaum JA, Labarthe DR. Evaluation of AAP guidelines for cholesterol screening in youth: project HeartBeat! Am J Prev Med. 2009; 37:S71–S77. DOI: 10.1016/j.amepre.2009.04.008. PMID: 19524159. PMCID: PMC2743187.

33. Ritchie SK, Murphy ECS, Ice C, Cottrell LA, Minor V, Elliott E, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics. 2010; 126:260–265. DOI: 10.1542/peds.2009-2546. PMID: 20624798.

34. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non–high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics. 2006; 118:201–206. DOI: 10.1542/peds.2005-1856. PMID: 16818566.

35. Shin JH, Cheong JI, Cheuh HW, Yoo JH. Limitations of current screening methods for lipid disorders in Korean adolescents and a proposal for an effective detection method: a nationwide, cross-sectional study. Ann Pediatr Endocrinol Metab. 2020; 25:265–271. DOI: 10.6065/apem.2040098.049. PMID: 33401883. PMCID: PMC7788341.

36. Lim JS. The current state of dyslipidemia in Korean children and adolescents and its management in clinical practice. Ann Pediatr Endocrinol Metab. 2013; 18:1–8. DOI: 10.6065/apem.2013.18.1.1. PMID: 24904843. PMCID: PMC4027065.

37. Hong HR, Kim SU, Kang HS. Physical activity and metabolic syndrome in Korean children. Int J Sports Med. 2009; 30:677–683. DOI: 10.1055/s-0029-1224172. PMID: 19569013.

38. McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary guidelines for Americans, 2010. 7th edition, Washington, DC: U.S. Government Printing Office, January 2011. Adv Nutr. 2011; 2:293–294. DOI: 10.3945/an.111.000430. PMID: 22332062. PMCID: PMC3090168.

39. Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019; 381:1547–1556. DOI: 10.1056/NEJMoa1816454. PMID: 31618540.

40. Najam O, Ray KK. Familial hypercholesterolemia: a review of the natural history, diagnosis, and management. Cardiol Ther. 2015; 4:25–38. DOI: 10.1007/s40119-015-0037-z. PMID: 25769531. PMCID: PMC4472649.

41. Manlhiot C, Larsson P, Gurofsky RC, Smith RW, Fillingham C, Clarizia NA, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009; 123:458–465. DOI: 10.1542/peds.2008-0367. PMID: 19171610.

42. Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. J Clin Endocrinol Metab. 2014; 99:3093–3102. DOI: 10.1210/jc.2013-3860. PMID: 24848708.

43. Chauhan A, Paunikar P. Update on pediatric hyperlipidemia. Curr Opin Pediatr. 2014; 26:252–258. DOI: 10.1097/MOP.0000000000000078. PMID: 24553633.

44. Alwaili K, Alrasadi K, Awan Z, Genest J. Approach to the diagnosis and management of lipoprotein disorders. Curr Opin Endocrinol Diabetes Obes. 2009; 16:132–140. DOI: 10.1097/MED.0b013e328329135a. PMID: 19306526.

45. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002; 106:2231–2237. DOI: 10.1161/01.CIR.0000035247.42888.82. PMID: 12390953.

46. Mendelson MM, Regh T, Chan J, Baker A, Ryan HH, Palumbo N, et al. Correlates of achieving statin therapy goals in children and adolescents with dyslipidemia. J Pediatr. 2016; 178:149–155. DOI: 10.1016/j.jpeds.2016.08.003. PMID: 27592099. PMCID: PMC5085848.

47. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007; 23:767–775. DOI: 10.1185/030079907X182059. PMID: 17407633.

48. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008; 52:1421–1429. DOI: 10.1016/j.jacc.2008.09.002. PMID: 18940534.

49. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993; 92:78–82. DOI: 10.1542/peds.92.1.78. PMID: 8516088.

50. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97:2969–2989. DOI: 10.1210/jc.2011-3213. PMID: 22962670. PMCID: PMC3431581.